Why some people with chronic lymphocytic leukemia respond to BTK degrader drugs
Official title: Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Run by Nantes University Hospital · NCT07099443 · Data updated 2026-11-12
This project collects blood, bone marrow, or leftover lymph node samples from adults with CLL who are candidates for or have received BTK degrader drugs to see why some people respond and others become resistant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 14 sites (Angers and 13 other locations) |
| Status | Recruiting |
| Started | October 9, 2025 |
| Main results expected | September 15, 2039 |
| Study ends | September 15, 2039 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT07099443 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with CLL who are candidates for or have been treated with BTK degrader drugs, can give informed consent, and are covered by French social security are eligible.
✕Probably not a fit
Children, adults under guardianship, and other legally protected persons are excluded and are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort creates a biobank of blood, bone marrow and residual lymph node biopsy samples from CLL patients who are candidates for or have been exposed to BTK degraders. Extra samples are collected alongside routine clinical care after informed consent, with no experimental treatment assigned by the protocol. Laboratory analyses will be used to study molecular mechanisms of response and resistance to BTK degraders, particularly in patients previously treated with BTK and BCL-2 inhibitors. The cohort is led by Nantes University Hospital with sample collection at participating centers in Angers and Bordeaux, France.
Why it matters
Potential benefit: If successful, the biobank could identify biomarkers that predict response or resistance to BTK degraders and guide better treatment choices for CLL patients.
How similar studies have gone: Biobanking and molecular studies have previously identified resistance mechanisms to BTK inhibitors, but applying these methods specifically to the new class of BTK degraders is novel and early-stage.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with CLL candidates ou exposed to BTKd * Patient who has provided informed consent to participate in the study. * Patient covered by a social security health insurance plan Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons.
Where it's running
-
CHD Vendée
La Roche-sur-Yon, France Recruiting -
University Hospital
Nantes, France Recruiting -
CHU de Angers
Angers, France Not yet recruiting -
CHU de Bordeaux
Bordeaux, France Not yet recruiting -
Institut Bergonié
Bordeaux, France Not yet recruiting -
CHU de Clermont-Ferrand
Clermont-Ferrand, France Not yet recruiting
Show 8 more locations
-
Centre Léon Bernard
Lyon, France Not yet recruiting -
Institut Paoli-Calmettes (Marseille)
Marseille, France Not yet recruiting -
CHU de Montpellier
Montpellier, France Not yet recruiting -
CH Régional Universitaire de Nancy
Nancy, France Not yet recruiting -
Hôpital Avicenne (AP-HP)
Paris, France Not yet recruiting -
Hôpital Universitaire Pitié Salpêtrière de Paris
Paris, France Not yet recruiting -
CHU de Poitiers
Poitiers, France Not yet recruiting -
Centre Henri-Becquerel de Rouen
Rouen, France Not yet recruiting
Study contacts
- Principal investigator: Anne LOK, MD, PhD — Hospital of Nantes
- Study coordinator: ANNE LOK, Dr
- Email: anne.lok@chu-nantes.fr
- Phone: 02.40.08.42.11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients
This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.
-
Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL
This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.
-
Nemtabrutinib and venetoclax in untreated CLL/SLL
This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
NX-5948 plus other medicines for B-cell cancers
This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.
-
NX-5948 vs Pirtobrutinib in R/R CLL/SLL
This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.